- Home
- BANX vs TNYA Comparison
BANX vs TNYA Comparison
Compare BANX & TNYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BANX | TNYA |
|---|---|---|
| Founded | 2013 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 172.0M | 157.9M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | BANX | TNYA |
|---|---|---|
| Price | $21.21 | $0.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.25 |
| AVG Volume (30 Days) | 23.4K | ★ 3.4M |
| Earning Date | 06-17-2025 | 03-09-2026 |
| Dividend Yield | ★ 9.66% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.35 | N/A |
| Revenue | ★ $29,467,794.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.88 | ★ N/A |
| Revenue Growth | ★ 2.73 | N/A |
| 52 Week Low | $17.99 | $0.36 |
| 52 Week High | $21.67 | $2.35 |
Technical Indicators
Market Signals| Indicator | BANX | TNYA |
|---|---|---|
| Relative Strength Index (RSI) | 40.24 | 42.63 |
| Support Level | $21.20 | $0.67 |
| Resistance Level | $21.79 | $0.78 |
| Average True Range (ATR) | 0.37 | 0.05 |
| MACD | -0.08 | 0.02 |
| Stochastic Oscillator | 40.99 | 58.44 |
Price Performance
Historical ComparisonAbout BANX ArrowMark Financial Corp.
ArrowMark Financial Corp is a non-diversified, closed-end management investment company. Its objective is to provide stockholders with current income, and to a lesser extent capital appreciation. The company's investments in various portfolios such as debt securities, Trust Preferred and Preferred Securities, preferred securities, exchange-traded funds, money market funds and others.
About TNYA Tenaya Therapeutics Inc.
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration and precision medicine.